Crossmark

Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists

Published Online: 2020-02-13

Published Print: 2020-05

Authors

Schilling, Uta http://orcid.org/0000-0003-2483-8222
Dingemanse, Jasper

Ufer, Mike
License Information

Text and Data Mining valid from 2020-02-13

Version of Record valid from 2020-02-13
More Information

Article History

First Online: 13 February 2020

Compliance with Ethical Standards

:

: The studies involving selatogrel discussed in this review were funded by Idorsia Pharmaceuticals Ltd.

: Uta Schilling is a full-time employee of Idorsia Pharmaceuticals Ltd. Mike Ufer and Jasper fDingemanse are full-time employees of Idorsia Pharmaceuticals Ltd and owners of stocks/ stock options. Selatogrel is currently in development by Idorsia Pharmaceuticals Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article.

Document is current